Business & FinanceTop StoryTop StoryLatest News
Biocon Expands Global Reach of Stelara Biosimilar to Nine More Markets
Sentiment: NeutralHigh Priority
What Happened?
Biocon Limited has signed a license agreement with Janssen Sciences to commercialize its Stelara biosimilar, Yesintek, in nine additional markets, including Australia and Brazil. The agreement allows immediate sales in these regions.
Key points
- Biocon can now sell Yesintek in Australia, Brazil, China, Hong Kong, Israel, Mexico, New Zealand, South Korea, and Kazakhstan.
- The agreement adds to previous settlements with Janssen for market entry in the US, Europe, UK, Canada, and Japan.
- Stelara, the reference brand, had worldwide sales of $6.08 billion in 2025.
- Yesintek is approved for conditions like Crohn's disease and plaque psoriasis.
- Product launches are subject to regulatory approval in each market.
Key insights
- The expansion may increase Biocon's market share in the biosimilar sector.
- Access to new markets could enhance competition against Stelara.
- Regulatory approvals will be crucial for successful product launches.
Why it matters
This expansion could provide affordable treatment options for autoimmune disease patients in new markets.
Tags
Entities
Biocon Limited· CompanyJanssen Sciences Ireland· CompanyStelara· ProductYesintek· ProductAustralia· CountryBrazil· CountryChina· CountryHong Kong· LocationIsrael· CountryMexico· CountryNew Zealand· CountrySouth Korea· CountryKazakhstan· Country
Source
Business Standard
